Join us on Thursday, October 29th, at 8 am PST (11 am EST) for our new webinar, “Discovery & Characterization of ORM-11372 (A Unique and Positive Inotropic Sodium-Calcium Exchanger/Inhibitor: Implications for Heart Failure Drug Discovery),” presented by Jouko Levijoki, Senior Research Scientist at Orion Corporation. The lack of selective sodium-calcium exchanger (NCX) inhibitors has hampered the exploration of physiological and pathophysiological roles of cardiac NCX 1.1. Levijoki and his team aimed to discover a more potent and selective drug like NCX 1.1. inhibitor. ORM-11372, a unique, novel, and potent inhibitor of human and rat NCX 1.1, is a positive inotropic compound. NCX inhibition can induce clinically relevant improvements in left ventricular contractions without affecting relaxation, heart rate or blood pressure–without pro-arrhythmic risk. Levijoki has worked at Orion Corporation for more than 30 years in various capacities, including pharmacologist and head of nonclinical cardiovascular research. He received his Master of Science in Pharmacology from the University of Helsinki.